Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05227547 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease

Study acronym: CoStemCells
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 31, 2025 to Oct 5, 2030v7
  2. Collaborators expanded, about 15 wordsv6
  3. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Dec 31, 2024 to Oct 31, 2025
    • Study completion date: Apr 1, 2027 to Oct 5, 2030
    • Start date changed from estimate of Sep 30, 2022 to Oct 5, 2022
    • Site details revised at 4 of 4 sites
  4. Start date: May 30, 2022 to Sep 30, 2022v4
  5. Start date: Mar 30, 2022 to May 30, 2022v3
  6. Start date: Feb 15, 2022 to Mar 30, 2022v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the regenerative capacities of mesenchymal cells composing the microenvironment of alveolar type 2 cells in a population of patients, undergoing thoracic surgery for suspected cancer, who are smokers with and without COPD compared to non-smokers patients
Trial Details
NCT Number NCT05227547
Lead Sponsor Centre Hospitalier Intercommunal Creteil
Collaborators: Henri Mondor University Hospital, Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)		 Chronic Obstructive Lung Disease, Chronic Obstructive Pulmonary Disease
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 186 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov